List of Figures
Figure 1: Management of COPD
Figure 2: Global COPD Drugs Market Size, By Value, 2013-2017 (USD Million)
Figure 3: Smoking Prevalence Among Adults, By Gender, 2015
Figure 4: Cigarette Sales Share, By Region, 2017 (% of total)
Figure 5: Deaths Due To Air Pollution, By Disease Type, 2016
Figure 6: Percentage of NCD Cases Due to Air Pollution, 2016
Figure 7: Global PM2.5 air pollution, mean annual exposure, 2012-2016
Figure 8: Global Aged Population(Above 65), By Country, 2017 (% of total)
Figure 9: Global Aged Population (Above 65), 2013-2017 (% of total)
Figure 10: Global Overweight Population (Age above 18), 2013-2016 (% of total)
Figure 11: Global Overweight Population (Age above 18), By Sex, 2016 (% of total)
Figure 12: COPD Facts and Figures
Figure 13: Generic Market Value Share, In 2006 (Left) &2016 (Right), By Region
Figure 14: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %)
Figure 15: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
Figure 16: Expected Global Medical Spending in 2020, By Region, (% of Total)
Figure 17: COPD DAYLs Per 100000, By Country, All Sex, All Age,2017
Figure 18: GDP Per Capita PPP, By Region, 2018 (in Thousand USD)
Figure 19: Global Expected Healthcare Industry Outlook
Figure 20: Regional Expected Healthcare Industry Growth Rate By Year 2020
Figure 21: Regional Expected Healthcare Industry Growth Rate By Year 2020
Figure 22: Global COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 23: Global COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 24: Global Combination Therapy COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 25: Global Combination Therapy COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 26: Global Anticholinergics COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 27: Global Anticholinergics COPD Drugs Market, 2018-2023(USD Million)
Figure 28: Global Beta-Agonist COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 29: Global Beta-Agonist COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 30: Global ICS COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 31: Global ICS COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 32: Global Other COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 33: Global Other COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 34: Global Market Attractiveness, By Product Type, 2023F
Figure 35: Global COPD Drugs Market Size, By Region, 2017 (%)
Figure 36: Global COPD Drugs Market Size, By Region, 2023F (%)
Figure 37: North America COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 38: United States Spending on Medicines, 2013-2017 (In USD Billion)
Figure 39: Patented and Non-Patented Drugs Sales in Canada, 2013-2016 (USD Billion)
Figure 40: North America, Smoking Prevalence, Age 15+, 2013-2016
Figure 41: North America, Smoking Prevalence, Age 15+, 2013-2016
Figure 42: United States health care expenditure per capita,2013-2016(USD)
Figure 43: Canada health care expenditure per capita,2013-2016(USD)
Figure 44: North America population aged 65 and above, 2013-2017 (% of total)
Figure 45: North America Healthcare Cost Per Capita, 2017 (USD)
Figure 46: North America GDP per Capita, 2013-2017 (USD)
Figure 47: North America COPD Drugs Market, By Value, 2018-2023 (USD Million)
Figure 48: North America COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 49: North America COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 50: North America COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 51: North America COPD Drugs Market, By Drug Type, By Value, 2018-2023(USD Million)
Figure 52: North America COPD Drugs Market Size, By Countries, 2017 (%)
Figure 53: North America COPD Drugs Market Size, By Countries, 2023F (%)
Figure 54: USA COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 55: USA COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 56: Smoking Prevalence, Age 15+, 2012-2016
Figure 57: Canada, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
Figure 58: United States Per Capita Spending on Medicines, 2013-2017 (In USD)
Figure 59: Pharmacy & Drug Store Sales in United States, 2013-2016 (In USD Billion)
Figure 60: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million)
Figure 61: U.S., Population ages 65 and above, 2013-2017 (% of total)
Figure 62: U.S., Population ages 65 and above, Forecast (In Millions)
Figure 63: U.S., Per Capita Expenditure on Healthcare, 2012-2018E (In USD)
Figure 64: U.S., GDP (Current USD), 2013-2017 (In USD Trillion)
Figure 65: USA COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 66: USA COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 67: USA COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 68: USA COPD Drugs Market, By Drug Type, By Value, 2018-2023(USD Million)
Figure 69: Canada COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 70: Canada COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 71: Percentage Change in Deaths Between, 2007-2017 Due to Respiratory Diseases
Figure 72: Canada, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
Figure 73: Canada, Smoking Prevalence, Age 15+, 2012-2016
Figure 74: Number of Retail Pharmacies in Canada, 2013-2017
Figure 75: Number of Hospitals Establishments in Canada, By Province, 2015
Figure 76: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
Figure 77: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
Figure 78: Canada, Population ages 65 and above, 2012-2017 (% of total)
Figure 79: Canada COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 80: Canada COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 81: Canada COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 82: Europe COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 83: Europe Health Expenditure, By Select Country, 2016 (% of GDP)
Figure 84: Europe Population ages 65 years and above (% of total population), 2013-17
Figure 85: European Union, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
Figure 86: European Union, Smoking Prevalence, Age 15+, 2012-2016
Figure 87: Cause of Death, EU-28, 2015, Per 1000000 inhabitants, Both Sex
Figure 88: Europe, COPD Prevalence, By Selected Countries, 2017, (In Million)
Figure 89: Mean Average Age At Which Majority of Population Affected By COPD, By Region
Figure 90: Europe COPD Drugs Market, By Value, 2018-2023 (USD Million)
Figure 91: Europe COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 92: Europe COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 93: Europe COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 94: Europe COPD Drugs Market Size, By Countries, 2017 (%)
Figure 95: Europe COPD Drugs Market Size, By Countries, 2023F (%)
Figure 96: Germany COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 97: Germany COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 98: Germany COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions)
Figure 99: PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
Figure 100: Germany, Population ages 65 and above, 2012-2017 (% total)
Figure 101: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
Figure 102: Germany, Healthcare Related Statistics, 2017
Figure 103: Germany, Smoking Prevalence, Age 15+, 2012-2016, (% of Total)
Figure 104: Germany, Percentage Change In Cause of Death Between 2007-2017
Figure 105: Germany COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 106: Germany COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 107: Germany COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 108: France COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 109: France COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 110: France, COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions)
Figure 111: France, Smoking Prevalence, Age 15+, 2012-2017, (% of Total)
Figure 112: France, Healthcare Infrastructure Related Statistics
Figure 113: France, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2017
Figure 114: France, Health Expenditure, (% of GDP), 2012-2015 (USD)
Figure 115: France, Population Ages 65 and Above (% of total), 2012-2017
Figure 116: France, Cause of Death, 2017, (% of Total)
Figure 117: France, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 118: France COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 119: France COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 120: France COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 121: U.K COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 122: U.K COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 123: Germany, COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions)
Figure 124: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD)
Figure 125: U.K, Population Ages 65 and Above (% of total), 2012-2017
Figure 126: U.K, Population Ages 65 and Above (% of total), 2012-2017
Figure 127: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 128: UK, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2017
Figure 129: UK, Smoking Prevalence (% of Total), 2012-2017
Figure 130: U.K COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 131: U.K COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 132: U.K COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 133: Italy COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 134: Italy COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 135: Italy COPD Prevalence, 2013-2017, 2018E-2023E, (in Millions)
Figure 136: Italy, Health Expenditure, (% of GDP), 2013-2017 (USD)
Figure 137: Italy, Population Ages 65 and Above (% of total), 2012-2017
Figure 138: Italy, Healthcare Infrastructure Related Statistics
Figure 139: Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 140: Italy, Smoking Prevalence, Age 15+, 2012-2016
Figure 141: Italy, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter) 2012-2016
Figure 142: Italy COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 143: Italy COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 144: Italy COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 145: APAC COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 146: GDP Per Capita in APAC, By Select Country, 2016 (In USD)
Figure 147: Population ages 65 and above, By Select Country, 2017 (% of total)
Figure 148: Men Smoking Prevalence in Asia, 2016, (% of Total Population)
Figure 149: East Asia & Pacific, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
Figure 150: South Asia, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
Figure 151: China, Pharmaceuticals Industry Revenue (USD Billion)
Figure 152: Japan, Total Drugs Market, 2013-2017, USD Billion
Figure 153: India Pharma Market, 2015-2017, (USD Billion)
Figure 154: APAC COPD Drugs Market, By Value, 2018-2023 (USD Million)
Figure 155: APAC COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 156: APAC COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 157: APAC COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 158: APAC COPD Drugs Market Size, By Countries, 2017 (%)
Figure 159: APAC COPD Drugs Market Size, By Countries, 2023F (%)
Figure 160: China COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 161: China COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 162: China, Smoking Prevalence, Age 15+, % of Total Population, 2012-2016
Figure 163: China, Tobacco Attributable Deaths, 2030
Figure 164: China, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
Figure 165: Beijing annual PM2.5 air pollution levels, 2013-2017, (in micrograms per cubic meter of air)
Figure 166: China Co2 Emissions, 2013-2016 (Billion Metric Tons)
Figure 167: China, Population Above 65 (% of Total), 2013-2017
Figure 168: China, GDP Growth Per Year, 2015-2019 (In %)
Figure 169: China, Share of Urban Population, 2012-2017 (In %)
Figure 170: China, Total Population, 2013-2021F (In Billion)
Figure 171: China COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 172: China COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 173: China COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 174: Japan COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 175: Japan COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 176: Japan, Population ages 65 and above, 2012-2017 (% of total)
Figure 177: Japan, Smoking Prevalence, Age 15+, 2012-2016, (% of Total Prevalence)
Figure 178: Japan, Medical Facilities Outlook
Figure 179: Japan Healthcare Expenditure Outlook (%)
Figure 180: Japan, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
Figure 181: Japan, GDP Growth Per Year, 2015-2019F (In %)
Figure 182: Japan COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 183: Japan COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 184: Japan COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 185: India COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 186: India COPD Drugs Market, By Value, 2018-2023(USD Million)
Figure 187: India, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2017
Figure 188: India, Smoking Prevalence, Age 15+, 2012-2016, (% of Total)
Figure 189: India, Diseases & Medical Industry Outlook
Figure 190: India, Population ages 65 and above, 2013-2017
Figure 191: India, Total Population, 2013-2023F (In Billion)
Figure 192: Pharma Export From India Market, 2013-2017, (USD Billion)
Figure 193: India COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 194: India COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 195: India COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 196: ROW COPD Drugs Market, By Value, 2013-2017 (USD Million)
Figure 197: South Africa, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2013-2016
Figure 198: South Africa, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2013-2016
Figure 199: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
Figure 200: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
Figure 201: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
Figure 202: Middle East and North Africa, Population ages 65 and above (% of total)
Figure 203: ROW COPD Drugs Market, By Value, 2018-2023 (USD Million)
Figure 204: ROW COPD Drugs Market Size, By Drug Type, 2017 (%)
Figure 205: ROW COPD Drugs Market Size, By Drug Type, 2023F (%)
Figure 206: ROW COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 207: Exacerbation During the Study Over a Period of 12 Months (Part B)
Figure 208: Percentage aged 60 years and over, (2000, 2015, 2030,2050)
Figure 209: COPD-Major Drugs Sales, By Drug Type, 2017 (USD Million)
Figure 210: GSK COPD Drugs Sales, 2018-2023 Estimated, USD Million
Figure 211: AstraZeneca COPD Drugs Sales, 2018-2023 Estimated, USD Million
Figure 212: Novartis COPD Drugs Sales, 2018-2023 Estimated, USD Million
Figure 213: COPD-Major Drugs Sales, By Drug Type, 2017 (USD Million)
Figure 214: GSK, Revenues, 2013-2017 (USD Million)
Figure 215: GSK, Revenues, 2013-2017 (USD Million)
Figure 216: GSK, Revenue, By Segments, 2017(%)
Figure 217: GSK, Revenue, By Pharmaceuticals Segment, 2017 (USD Million)
Figure 218: GSK COPD Drugs Patent Expiry Details
Figure 219: GSK, Respiratory Segment Expected Revenue By 2023 (USD Million)
Figure 220: AstraZeneca, Net Sales, 2013-2017 (USD Million)
Figure 221: AstraZeneca Revenue, By Segments, 2017(%)
Figure 222: AstraZeneca Revenue, By Region, 2017(%)
Figure 223: Boehringer-Ingelheim, Net Sales, 2013-2017 (USD Million)
Figure 224: Boehringer-Ingelheim, By Segments, 2017(%)
Figure 225: Boehringer-Ingelheim, By Region, 2017(%)
Figure 226: Teva Pharmaceuticals, Net Sales, 2013-2017 (USD Million)
Figure 227: Teva Pharmaceuticals, By Segments, 2017(%)
Figure 228: Teva Pharmaceuticals, By Region, 2017(%)
Figure 229: Chiesi Farmaceutici S.p.A., Net Sales, 2013-2017 (USD Million)
Figure 230: Chiesi Farmaceutici S.p.A., By Segments, 2017(%)
Figure 231: Chiesi Farmaceutici S.p.A., By Segments, 2017(%)
Figure 232: Novartis, Net Sales, 2013-2017 (USD Million)
Figure 233: Novartis, Revenue, By Segment, 2017(%)
Figure 234: Novartis, Revenue, By Region, 2017(%)
Figure 235: Cipla, Net Sales, 2013-2017 (USD Million)
Figure 236: Cipla, By Region, 2017(%)
Figure 237: Mylan, Net Sales, 2013-2017 (USD Million)
Figure 238: Mylan, By Region, 2017(%)
Figure 239: Vectura Group, Net Sales, 2013-2017 (USD Million)
Figure 240: Vectura Group, By Products, 2017(%)
